{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:28:40Z","timestamp":1792700920906,"version":"4.5.0"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Olanzapine, aripiprazole and risperidone are atypical antipsychotics or neuroleptics widely used for schizophrenia treatment. They induce various adverse drug reactions depending on their mechanisms of action: metabolic effects, such as weight gain and alterations of glucose and lipid metabolism; hyperprolactinemia and extrapyramidal effects, such as tremor, akathisia, dystonia, anxiety and distress. In this review, we listed polymorphisms associated with individual response variability to olanzapine, aripiprazole and risperidone. Olanzapine is mainly metabolized by cytochrome P450 enzymes, CYP1A2 and CYP2D6, whereas aripiprazole and risperidone metabolism is mainly mediated by CYP2D6 and CYP3A4. Polymorphisms in these genes and other enzymes and transporters, such as enzymes from the uridine 5'-diphospho-glucuronosyltransferase (UGT) family and ATP-binding cassette sub-family B member 1 (ABCB1), are associated to differences in pharmacokinetics. The three antipsychotics act on dopamine and serotonin receptors, among others, and several studies found associations between polymorphisms in these genes and variations in the incidence of adverse effects and in the response to the drug. Since olanzapine is metabolized by CYP1A2, a lower starting dose should be considered in patients treated with fluvoxamine or other CYP1A2 inhibitors. Regarding aripiprazole, a reduced dose should be administered in CYP2D6 poor metabolizers (PMs). Additionally, a reduction to a quarter of the normal dose is recommended if the patient is treated with concomitant CYP3A4 inhibitors. Risperidone dosage should be reduced for CYP2D6 PMs and titrated for CYPD6 ultrarapid metabolizers (UMs). Moreover, risperidone dose should be evaluated when a CYP2D6, CYP3A4 or ABCB1 inhibitor is administered concomitantly.<\/jats:p>","DOI":"10.3389\/fphar.2021.711940","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T07:43:29Z","timestamp":1626248609000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone"],"prefix":"10.3389","volume":"12","author":[{"given":"Paula","family":"Soria-Chacartegui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/fcp.12424","article-title":"Dopamine (DRD 2) and Serotonin ( HTR 2A, 2C) Receptor Gene Polymorphisms Do Not Influence Early Response to Risperidone in South Indian Patients with Schizophrenia","volume":"33","author":"Alladi","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular Targets of Atypical Antipsychotics: From Mechanism of Action to Clinical Differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS ONE"},{"key":"B4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cpt.762","article-title":"Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group","volume":"103","author":"Bank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on Weight-Gain Caused by Antipsychotics: a Systematic Review and Meta-Analysis","volume":"19","author":"Barton","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2174\/1389450043345263","article-title":"The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and its Clinical Relevance for Drug Interactions","volume":"5","author":"Berecz","year":"2004","journal-title":"CDT"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/ajhp\/55.10.1003","article-title":"Olanzapine: a Serotonin-Dopamine-Receptor Antagonist for Antipsychotic Therapy","volume":"55","author":"Bever","year":"1998","journal-title":"Am. J. Health-System Pharm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","article-title":"Olanzapine","volume":"61","author":"Bhana","year":"2001","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/070674371405900203","article-title":"Pharmacogenetics of Antipsychotics","volume":"59","author":"Brandl","year":"2014","journal-title":"Can. J. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2217\/pgs.14.50","article-title":"Pharmacogenetics of Second-Generation Antipsychotics","volume":"15","author":"Brennan","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fpsyt.2014.00047","article-title":"The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/hup.2308","article-title":"Polymorphisms Influencing Olanzapine Metabolism and Adverse Effects in Healthy Subjects","volume":"28","author":"Cabaleiro","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"B14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hup.2420","article-title":"Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers","volume":"29","author":"Cabaleiro","year":"2014","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"B15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process","volume":"15","author":"Caudle","year":"2014","journal-title":"CDM"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1159\/000494573","article-title":"Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis","volume":"50","author":"Chen","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-009-1538-z","article-title":"HTR2A A-1438G\/T102C Polymorphisms Predict Negative Symptoms Performance upon Aripiprazole Treatment in Schizophrenic Patients","volume":"205","author":"Chen","year":"2009","journal-title":"Psychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/0269881119872193","article-title":"An Open-Label Randomised Comparison of Aripiprazole, Olanzapine and Risperidone for the Acute Treatment of First-Episode Schizophrenia: Eight-Week Outcomes","volume":"33","author":"Cheng","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative Pharmacology of Risperidone and Paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs R. D"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4088\/jcp.v62n0310","article-title":"Cardiac Safety Parameters of Olanzapine: Comparison with Other Atypical and Typical Antipsychotics","volume":"62","author":"Czekalla","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FTD.0000000000000119","article-title":"CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations","volume":"37","author":"Czerwensky","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"B24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0001-7310(06)73482-2","article-title":"Farmacogen\u00e9tica I. Concepto, historia, objetivos y \u00e1reas de estudio","volume":"97","author":"Daud\u00e9n Tello","year":"2006","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/1099800409358760","article-title":"Functional SNPs in Genes Encoding the 5-HT2A Receptor Modify the Affinity and Potency of Several Atypical Antipsychotic Drugs","volume":"13","author":"Davies","year":"2011","journal-title":"Biol. Res. Nurs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/1389201018666170224105600","article-title":"Clinical Applications of Personalized Medicine: A New Paradigm and Challenge","volume":"18","author":"Di Sanzo","year":"2017","journal-title":"CPB"},{"key":"B27","unstructured":"EMA Recommendations on DPD Testing Prior to Treatment with Fluorouracil, Capecitabine, Tegafur and Flucytosine\n            Ema\n          2020"},{"key":"B28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","article-title":"Olanzapine Metabolism and the Significance of UGT1A448V and UGT2B1067Y Variants","volume":"21","author":"Erickson-Ridout","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"key":"B29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.31887\/DCNS.2016.18.3\/jbishop","article-title":"Pharmacogenetic Tests for Antipsychotic Medications: Clinical Implications and Considerations","volume":"18","author":"Eum","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of Risperidone to 9-hydroxyrisperidone by Human Cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn-schmiedeberg's Arch. Pharmacol."},{"key":"B32","unstructured":"ABILIFY (Aripiprazole). HIGHLIGHTS of PRESCRIBING INFORMATION2014"},{"key":"B33","unstructured":"ABILIFY MAINTENA (Aripiprazole). HIGHLIGHTS of PRESCRIBING INFORMATION2016"},{"key":"B34","unstructured":"RISPERIDAL (Risperidone). HIGHLIGHTS of PRESCRIBING INFORMATION1993"},{"key":"B35","unstructured":"ZIAGEN (Abacavir Sulfate). HIGHLIGHTS of PRESCRIBING INFORMATION2019"},{"key":"B36","unstructured":"ZYPREXA (Olanzapine). HIGHLIGHTS of PRESCRIBING INFORMATION1996"},{"key":"B37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.18433\/J3H63T","article-title":"DRD3 Ser9Gly Polymorphism and its Influence on Risperidone Response in Autistic Children","volume":"20","author":"Firouzabadi","year":"2017","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.clinthera.2016.07.110","article-title":"The Role of Cyp2d6, Cyp3a4\/5, and Abcb1 Polymorphisms in Patients Using Long-Acting Injectable Risperidone","volume":"38","author":"Ganoci","year":"2016","journal-title":"Clin. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"110042","DOI":"10.1016\/j.pnpbp.2020.110042","article-title":"ABCB1, ABCG2 and CYP2D6 Polymorphism Effects on Disposition and Response to Long-Acting Risperidone","volume":"104","author":"Ganoci","year":"2021","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B40","first-page":"313","article-title":"\u201cRisperidone,\u201d","volume-title":"Profiles of Drug Substances, Excipients and Related Methodology","author":"Germann","year":"2012"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death","volume":"158","author":"Glassman","year":"2001","journal-title":"AJP"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.2147\/NDT.S148824","article-title":"Potential Link between Genetic Polymorphisms of Catechol-O-Methyltransferase and Dopamine Receptors and Treatment Efficacy of Risperidone on Schizophrenia","author":"Han","year":"2017","journal-title":"NDT"},{"key":"B43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1871530315666150623092031","article-title":"Weight Gain and Metabolic Changes during Treatment with Antipsychotics and Antidepressants","volume":"15","author":"Himmerich","year":"2015","journal-title":"EMIDDT"},{"key":"B44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.psychres.2010.10.020","article-title":"Association of DRD2 and ANKK1 Polymorphisms with Prolactin Increase in Olanzapine-Treated Women","volume":"187","author":"Houston","year":"2011","journal-title":"Psychiatry Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1124\/dmd.104.001313","article-title":"EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM","volume":"32","author":"Huang","year":"2004","journal-title":"Drug Metab. Dispos"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2217\/14622416.9.10.1437","article-title":"Variants of Dopamine and Serotonin Candidate Genes as Predictors of Response to Risperidone Treatment in First-Episode Schizophrenia","volume":"9","author":"Ikeda","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40780-018-0126-y","article-title":"Association of CYP2D6 Polymorphisms and Extrapyramidal Symptoms in Schizophrenia Patients Receiving Risperidone: a Retrospective Study","volume":"4","author":"Ito","year":"2018","journal-title":"J. Pharm. Health Care Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3390\/ijms18102174","article-title":"Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome","volume":"18","author":"Jeon","year":"2017","journal-title":"IJMS"},{"key":"B49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the Dopamine D2 Receptor Gene and Their Relationships to Striatal Dopamine Receptor Density of Healthy Volunteers","volume":"4","author":"J\u00f6nsson","year":"1999","journal-title":"Mol. Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","article-title":"The Role of CYP2D6 and ABCB1 Pharmacogenetics in Drug-Na\u00efve Patients with First-Episode Schizophrenia Treated with Risperidone","volume":"66","author":"Jovanovi\u0107","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: an Open Randomised Clinical Trial","volume":"371","author":"Kahn","year":"2008","journal-title":"The Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-Week, Randomized, Double-Blind Study of Olanzapine versus Aripiprazole in the Treatment of Schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/JCP.0b013e3181a289e0","article-title":"Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients","volume":"29","author":"Kang","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/14737175.5.3.297","article-title":"Aripiprazole: Pharmacology, Efficacy, Safety and Tolerability","volume":"5","author":"Kinghorn","year":"2005","journal-title":"Expert Rev. Neurotherapeutics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.neuropharm.2010.06.010","article-title":"Pharmacokinetics of Acute and Sub-chronic Aripiprazole in P-Glycoprotein Deficient Mice","volume":"59","author":"Kirschbaum","year":"2010","journal-title":"Neuropharmacology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","article-title":"Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics","volume":"38","author":"Koller","year":"2021","journal-title":"Adv. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1177\/0269881118798605","article-title":"Effects of Aripiprazole on Pupillometric Parameters Related to Pharmacokinetics and Pharmacogenetics after Single Oral Administration to Healthy Subjects","volume":"32","author":"Koller","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/bcp.14300","article-title":"The Effects of Aripiprazole and Olanzapine on Pupillary Light Reflex and its Relationship with Pharmacogenetics in a Randomized Multiple\u2010dose Trial","volume":"86","author":"Koller","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B59","first-page":"CD006569","article-title":"Aripiprazole versus Other Atypical Antipsychotics for Schizophrenia","volume-title":"In The Cochrane Collaboration","author":"Komossa","year":"2009"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006626.pub2","article-title":"Risperidone versus Other Atypical Antipsychotics for Schizophrenia","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst. Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1124\/dmd.115.064790","article-title":"In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism","volume":"43","author":"Korprasertthaworn","year":"2015","journal-title":"Drug Metab. Dispos"},{"key":"B62","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.psychres.2007.06.006","article-title":"The Influence of 5-HT2C and MDR1 Genetic Polymorphisms on Antipsychotic-Induced Weight Gain in Female Schizophrenic Patients","volume":"160","author":"Kuzman","year":"2008","journal-title":"Psychiatry Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","article-title":"Taq1A Polymorphism in the Dopamine D2 Receptor Gene as a Predictor of Clinical Response to Aripiprazole","volume":"18","author":"Kwon","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic Medication in Schizophrenia: a Review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"B65","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","article-title":"PharmGKB Summary","volume":"22","author":"Lamba","year":"2012","journal-title":"Pharmacogenetics and Genomics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/aje\/kwj289","article-title":"Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia","volume":"164","author":"Lambert","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.159.9.1593","article-title":"Association of Risperidone Treatment Response with a Polymorphism in the 5-HT2AReceptor Gene","volume":"159","author":"Lane","year":"2002","journal-title":"AJP"},{"key":"B68","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1017\/S1461145704004389","article-title":"Effects of Dopamine D2 Receptor Ser311Cys Polymorphism and Clinical Factors on Risperidone Efficacy for Positive and Negative Symptoms and Social Function","volume":"7","author":"Lane","year":"2004","journal-title":"Int. J. Neuropsychopharm."},{"key":"B69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coph.2014.01.001","article-title":"Schizophrenia: from Dopaminergic to Glutamatergic Interventions","volume":"14","author":"Laruelle","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/FPC.0b013e32833ca24b","article-title":"DRD2 Promoter Region Variation Predicts Antipsychotic-Induced Weight Gain in First Episode Schizophrenia","volume":"20","author":"Lencz","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","article-title":"DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers","volume":"31","author":"L\u00f3pez-Rodr\u00edguez","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/13651501.2014.957705","article-title":"HTR2Cpolymorphisms, Olanzapine-Induced Weight Gain and Antipsychotic-Induced Metabolic Syndrome in Schizophrenia Patients: A Meta-Analysis","volume":"18","author":"Ma","year":"2014","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical Health Monitoring of Patients with Schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"AJP"},{"key":"B75","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ddr.21337","article-title":"Improving Current Treatments for Schizophrenia","volume":"77","author":"Maric","year":"2016","journal-title":"Drug Dev. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on Typical and Atypical Antipsychotic Drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.clinthera.2005.12.005","article-title":"Effects of Switching from Olanzapine to Risperidone on the Prevalence of the Metabolic Syndrome in Overweight or Obese Patients with Schizophrenia or Schizoaffective Disorder: Analysis of a Multicenter, Rater-Blinded, Open-Label Study","volume":"27","author":"Meyer","year":"2005","journal-title":"Clin. Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"The Lancet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jamapsychiatry.2018.1088","article-title":"Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths","volume":"75","author":"Nicol","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B80","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jpsychires.2017.09.008","article-title":"Risperidone versus Olanzapine Among Patients with Schizophrenia Participating in Supported Employment: Eighteen-Month Outcomes","volume":"95","author":"Noordsy","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","article-title":"Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers","volume":"30","author":"Novalbos","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The Relationship between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics","volume":"30","author":"Nozawa","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"B83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ijnp\/pyy061","article-title":"Smoking Rates and Number of Cigarettes Smoked Per Day in Schizophrenia: A Large Cohort Meta-Analysis in a Japanese Population","volume":"22","author":"Ohi","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/hup.2515","article-title":"Individual Differences Inin Vitroandin Vivometabolic Clearances of the Antipsychotic Drug Olanzapine from Non-smoking and Smoking Japanese Subjects Genotyped for Cytochrome P4502D6 and Flavincontaining Monooxygenase 3","volume":"31","author":"Okubo","year":"2016","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"B85","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41390-019-0305-z","article-title":"CYP2D6 Genotype and Adverse Events to Risperidone in Children and Adolescents","volume":"85","author":"Oshikoya","year":"2019","journal-title":"Pediatr. Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","article-title":"QTc Prolongation and Antipsychotic Medications in a Sample of 1017 Patients with Schizophrenia","volume":"34","author":"Ozeki","year":"2010","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B87","unstructured":"PharmVar2017"},{"key":"B88","unstructured":"Annotation of DPWG Guideline for Risperidone and CYP2D62020"},{"key":"B89","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1049909115612800","article-title":"Aripiprazole","volume":"34","author":"Prommer","year":"2017","journal-title":"Am. J. Hosp. Palliat. Care"},{"key":"B90","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","article-title":"The Predictive Value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 Polymorphisms for Risperidone and Aripiprazole Plasma Concentrations and the Occurrence of Adverse Drug Reactions","volume":"18","author":"Rafaniello","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e0127602","DOI":"10.1371\/journal.pone.0127602","article-title":"Association between Dopamine Receptor D2 (DRD2) Variations Rs6277 and Rs1800497 and Cognitive Performance According to Risk Type for Psychosis: A Nested Case Control Study in a Finnish Population Sample","volume":"10","author":"Ramsay","year":"2015","journal-title":"PLoS ONE"},{"key":"B92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C Receptor and Antipsychoticinduced Weight Gain - Mechanisms and Genetics","volume":"20","author":"Reynolds","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40519-018-0596-9","article-title":"DRD2\/ANKK1 TaqI A1 Polymorphism Associates with Overconsumption of Unhealthy Foods and Biochemical Abnormalities in a Mexican Population","volume":"24","author":"Rivera-I\u00f1iguez","year":"2019","journal-title":"Eat. Weight Disord."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"SCHBUL"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical Antipsychotic-Induced Weight Gain","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"B96","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/sj.mp.4001944","article-title":"Physiogenomic Comparison of Weight Profiles of Olanzapine- and Risperidone-Treated Patients","volume":"12","author":"Rua\u00f1o","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"B97","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head Comparisons of Metabolic Side Effects of Second Generation Antipsychotics in the Treatment of Schizophrenia: A Systematic Review and Meta-Analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophrenia Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/0269881119827959","article-title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 Affect Agomelatine Pharmacokinetics","volume":"33","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00228-017-2323-2","article-title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Tamoxifen Metabolism","volume":"73","author":"Sanchez Spitman","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B101","first-page":"1821","article-title":"Schizophrenia: a Review","volume":"75","author":"Schultz","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"B102","first-page":"53","article-title":"Aripiprazole-induced Asymptomatic Hypertension: A Case Report","volume":"47","author":"Seven","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jpsychires.2008.09.005","article-title":"Effects of DRD2\/ANKK1 Gene Variations and Clinical Factors on Aripiprazole Efficacy in Schizophrenic Patients","volume":"43","author":"Shen","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2217\/pgs.10.123","article-title":"Polymorphisms of theHTR2Cgene and Antipsychotic-Induced Weight Gain: an Update and Meta-Analysis","volume":"11","author":"Sicard","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B106","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/JCP.0b013e318204d9e2","article-title":"High Correlation between Serum and Cerebrospinal Fluid Olanzapine Concentrations in Patients with Schizophrenia or Schizoaffective Disorder Medicating with Oral Olanzapine as the Only Antipsychotic Drug","volume":"31","author":"Skogh","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":"Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients with Long-Term Antipsychotic Treatment","volume":"70","author":"Smith","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"B108","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.schres.2010.04.001","article-title":"Effects of Olanzapine and Risperidone on Lipid Metabolism in Chronic Schizophrenic Patients with Long-Term Antipsychotic Treatment: A Randomized Five Month Study","volume":"120","author":"Smith","year":"2010","journal-title":"Schizophrenia Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.psychres.2012.03.011","article-title":"Olanzapine and Risperidone Effects on Appetite and Ghrelin in Chronic Schizophrenic Patients","volume":"199","author":"Smith","year":"2012","journal-title":"Psychiatry Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2217\/pgs.13.120","article-title":"Pharmacogenetics of Olanzapine Metabolism","volume":"14","author":"S\u00f6derberg","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B111","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/tpj.2012.47","article-title":"Influence of FMO1 and 3 Polymorphisms on Serum Olanzapine and its N-Oxide Metabolite in Psychiatric Patients","volume":"13","author":"S\u00f6derberg","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00406-018-0880-8","article-title":"QTc Prolongation in Short-Term Treatment of Schizophrenia Patients: Effects of Different Antipsychotics and Genetic Factors","volume":"268","author":"Spellmann","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the Dopamine Hypothesis of Schizophrenia to Three Neural Networks of Psychosis: Dopamine, Serotonin, and Glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"B114","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/FTD.0000000000000070","article-title":"Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and its Active Metabolite, Dehydroaripiprazole, in Japanese Patients with Schizophrenia","volume":"36","author":"Suzuki","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"B115","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From Bench to Byte- an Update of Guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1517\/13543784.6.11.1743","article-title":"Olanzapine (Zyprexa):charactirestics of a New Antipsychotic","volume":"6","author":"Tamminga","year":"1997","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B117","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01213011-200504000-00002","article-title":"Polymorphisms of the 5-HT2C Receptor and Leptin Genes Are Associated with Antipsychotic Drug-Induced Weight Gain in Caucasian Subjects with a First-Episode Psychosis","volume":"15","author":"Templeman","year":"2005","journal-title":"Pharmacogenetics and Genomics"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e004216","DOI":"10.1136\/bmjopen-2013-004216","article-title":"Meta-analysis: the Effects of Smoking on the Disposition of Two Commonly Used Antipsychotic Agents, Olanzapine and Clozapine","volume":"4","author":"Tsuda","year":"2014","journal-title":"BMJ Open"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","article-title":"Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort","volume":"54","author":"Vandenberghe","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.dmpk.2016.01.005","article-title":"Detection of CYP2D6 Polymorphism Using Luminex xTAG Technology in Autism Spectrum Disorder: CYP2D6 Activity Score and its Association with Risperidone Levels","volume":"31","author":"Vanwong","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B121","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ajp.2017.05.004","article-title":"Neuroleptic Malignant Syndrome: A Neuro-Psychiatric Emergency: Recognition, Prevention, and Management","volume":"29","author":"Velamoor","year":"2017","journal-title":"Asian J. Psychiatry"},{"key":"B122","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of Antipsychotic Drugs as Inhibitors of Multidrug Resistance Transporter P-Glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology"},{"key":"B123","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jemermed.2017.06.026","article-title":"Risperidone in the Emergency Setting Is Associated with More Hypotension in Elderly Patients","volume":"53","author":"Wilson","year":"2017","journal-title":"J. Emerg. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clpt.2004.02.005","article-title":"CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy*1","volume":"75","author":"Wong","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/15622970801910399","article-title":"Blood Pressure Changes during Clozapine or Olanzapine Treatment in Korean Schizophrenic Patients","volume":"10","author":"Woo","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"B126","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2217\/14622416.7.7.987","article-title":"Polymorphisms of theABCB1gene Are Associated with the Therapeutic Response to Risperidone in Chinese Schizophrenia Patients","volume":"7","author":"Xing","year":"2006","journal-title":"Pharmacogenomics"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.pnpbp.2007.04.021","article-title":"Association between Major Multidrug Resistance 1 (MDR1) Gene Polymorphisms and Plasma Concentration of Prolactin during Risperidone Treatment in Schizophrenic Patients","volume":"31","author":"Yasui-Furukori","year":"2007","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B128","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/YCO.0000000000000417","article-title":"New Findings in Pharmacogenetics of Schizophrenia","volume":"31","author":"Zai","year":"2018","journal-title":"Curr. Opin. Psychiatry"},{"key":"B129","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4306\/pi.2016.13.2.232","article-title":"Olanzapine May Inhibit Colonic Motility Associated with the 5-HT Receptor and Myosin Light Chain Kinase","volume":"13","author":"Zhang","year":"2016","journal-title":"Psychiatry Investig."},{"key":"B130","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/YPG.0b013e328358629a","article-title":"Association between a COMT Polymorphism and Clinical Response to Risperidone Treatment","volume":"22","author":"Zhao","year":"2012","journal-title":"Psychiatr. Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"111087","DOI":"10.1016\/j.biopha.2020.111087","article-title":"Impact of Polymorphisms in Transporter and Metabolizing Enzyme Genes on Olanzapine Pharmacokinetics and Safety in Healthy Volunteers","volume":"133","author":"Zubiaur","year":"2021","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.711940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T07:43:41Z","timestamp":1626248621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.711940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":131,"alternative-id":["10.3389\/fphar.2021.711940"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.711940","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"article-number":"711940"}}